L-Arginine and Erectile Dysfunction
The purpose of the study is to determine whether the treatment with L-arginine leads to an improvement of erectile dysfunction in patients with erectile dysfunction.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||Oral Administration of L-Arginine in Patients With Erectile Dysfunction|
- International Index of Erectile Dysfunction [ Time Frame: 16 weeks ]
- L-arginine plasma-levels [ Time Frame: 16 weeks ]
|Study Start Date:||July 2003|
|Estimated Study Completion Date:||November 2005|
|Active Comparator: L-arginine||Drug: L-arginine|
|Placebo Comparator: placebo||Drug: Placebo|
Erectile dysfunction (ED) is a common medical disorder often affecting the aging male. Nitric oxide (NO) is a physiological signal essential to penile erection. NO synthase (NOS) catalyzes the production of NO from L-arginine. ADMA, a competitive inhibitor of NO synthase increases with age and many disorders that reduce NO in the erectile tissue are commonly associated with ED. Although new pharmacological strategies have been identified for medical treatment of ED, patients often seek alternative therapies for cost or side effect reasons.
The aim of the present study is to determine the efficacy of orally administered L-arginine on ED not caused by established organic disease.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00777075
|Institute of Clinical Pharmacology, Hannover Medical School|
|Hannover, Lower Saxony, Germany|
|Study Director:||Dirk O. Stichtenoth, MD||Institute of Clinical Pharmacology, Hannover Medical School|